AB Science S.A.
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III cl…
Drug Manufacturers - Specialty & Generic
FR, Paris [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 50.63 | -40.24 | -81.51 | |
| Graham Fair Price | 53.06 | 0.26 | 0.17 | |
| PEG | -30.32 | 1.19 | -1.71 | |
| Price/Book | -36.66 | -8.95 | -6.55 | |
| Price/Cash Flow | -100.00 | -24.74 | 0.00 | |
| Prices/Earnings | -25.32 | 129.54 | 173.47 | |
| Price/Sales | -25.32 | 360.33 | 482.52 | |
| Price/FCF | -100.00 | -24.74 | 0.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 67.60 | -1.15 | 0.69 | |
| Operating Margin | -30.07 | -11.41 | -8.77 | |
| ROA | 100.00 | 0.01 | 0.00 | |
| ROE | < 0.005 | -0.02 | -83.01 | |
| ROIC | 0.12 | -1.13 | 866.16 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | -1.00 | inf | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.79 | -1.60 | 102.61 | |
| EPS QOQ | 1.02 | 1.09 | 7.17 | |
| FCF QOQ | 1.00 | 0.00 | inf | |
| Revenue QOQ | -0.42 | 1.00 | 139.57 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 26.95 | 100.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 3285.17 | 100.00 | |
| Inventory Turnover | 0.00 | 3.34 | 100.00 | |
| Debt/Capitalization | 0.00 | -10.01 | -100.00 | |
| Quick Ratio | 0.00 | 1.34 | 100.00 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | -0.36 | -0.41 | -13.14 | |
| Cash | 0.28 | 0.12 | -57.53 | |
| Capex | 0.00 | < 0.005 | 100.00 | |
| Free Cash Flow | 0.00 | -0.15 | -100.00 | |
| Revenue | < 0.005 | 0.01 | 107.06 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad